Healthy Clinical Trial
Official title:
Gyrocardiography- A New Non-invasive Cardiac Measurement Method to Measure Exercise Capacity and Cardiorespiratory Fitness
The goal of this study is to produce a solution to measure the cardiorespiratory fitness (CRF), which can be used by commercially available smartphones without extra equipment, add-ons and special know-how. This observational study with follow-up is to test the feasibility of a new non-invasive cardiac measurement method (gyrocardiography, GCG) in detecting hemodynamic parameters to measure exercise capacity and cardiorespiratory fitness in healthy subjects. The objective is to produce a solution which can be used to measure the exercise capacity and cardiorespiratory fitness (CRF) of the exercisers, keep-fit athletes and professional athletes using hemodynamic parameters such as: - Heart rate and Heart rate variability - Cardiac Strength profile - Systolic and diastolic phase - Breathing frequency - VO2max Participants are either athletes or non-athletic persons. The athletes will perform spiroergometry and non-athletic persons ergometry to measure the CRF expressed as VO2max. Following parameters will be measured during the (spiro)ergometry: - Maximum workload (W) - VO2max (ml/kg/min) - HRmax - Blood lactate - Respiratory exchange ratio RER (VO2/VCO2) The GCG measurements for acquiring the hemodynamic parameters are performed before and after the (spiro)ergometry using smartphone. During a 1- minute GCG measurement, the smart phone is placed on the chest in the middle of the sternum.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Age: 18-65 years - No diagnosed cardiovascular diseases (mild hypertension or hypercholesterolemia are still allowed) - No medication affecting heart rate (i.e. Beta blocker) - Signed informed consent Follow-up visit: - Belong to non-athletic group - Intention to change physical activity habits - Willing to participate to the follow-up visit Exclusion Criteria: - Not meeting inclusion criteria - Declined to participate - Resting RR before the ergometry > 180/110mmHg |
Country | Name | City | State |
---|---|---|---|
Finland | Paavo Nurmi Center | Turku |
Lead Sponsor | Collaborator |
---|---|
Precordior Ltd | Paavo Nurmi Centre |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The maximum (max) rate (V) of oxygen (O2) your body is able to use during exercise. | 4 minutes | ||
Primary | Gyrocardiography measurement | Lasts 1 minute and is performed at least once at rest before the (spiro)ergometry. | 1 minute | |
Primary | Gyrocardiography measurement | Lasts 1 minute and is performed 3 minutes after the (spiro)ergometry. | 3 minutes | |
Secondary | Heart rate per minute and Heart rate variability | Lasts 1 minute and is performed at least once at rest before the (spiro)ergometry. | 1 minute | |
Secondary | Heart rate per minute and Heart rate variability | Lasts 1 minute and is performed 3 minutes after the (spiro)ergometry. | 3 minutes | |
Secondary | Systolic and diastolic phase (blood pressure RR) | Will be performed at least once at rest before the (spiro)ergometry. | 1 minute | |
Secondary | Respiration rate per minute | Lasts 1 minute and is performed at least once at rest before the (spiro)ergometry. | 1 minute | |
Secondary | Respiration rate per minute | Lasts 1 minute and is performed 3 minutes after the (spiro)ergometry. | 3 minutes | |
Secondary | Cardiac Strength profile | Lasts 1 minute and is performed at least once at rest before the (spiro)ergometry. | 1 minute | |
Secondary | Cardiac Strength profile | Lasts 1 minute and is performed 3 minutes after the (spiro)ergometry. | 3 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |